Is BRNS or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts prefer AIFC or BRNS?

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 452.49%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, AIFC or BRNS?

Barinthus Biotherapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.82 -$344.51M N/A N/A Barinthus Biotherapeutics $14.97M 1.98 -$66.43M -$1.29 N/A

Is BRNS or PYXS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% Pyxis Oncology N/A -135.60% -85.00%

Is BRNS or ONCY more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -63.83% -48.77% Oncolytics Biotech N/A -2,185.97% -321.54%

Barinthus Biotherapeutics (BRNS) Competitors

$0.72 +0.00 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$0.70 -0.02 (-3.18%)

As of 07:58 PM Eastern

Compare

BRNS vs. CYPH, COYA, AIFC, PYXS, and ONCY

Should you buy Barinthus Biotherapeutics stock or one of its competitors? MarketBeat compares Barinthus Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Barinthus Biotherapeutics include Cypherpunk Technologies (CYPH), Coya Therapeutics (COYA), ALT5 Sigma (AIFC), Pyxis Oncology (PYXS), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does Barinthus Biotherapeutics compare to Cypherpunk Technologies?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Barinthus Biotherapeutics has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

Cypherpunk Technologies has lower revenue, but higher earnings than Barinthus Biotherapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.98	-$66.43M	-$1.29	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Barinthus Biotherapeutics' score of 1.44 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Positive
Cypherpunk Technologies	Very Positive

Cypherpunk Technologies' return on equity of -48.33% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Barinthus Biotherapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 452.49%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Barinthus Biotherapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Barinthus Biotherapeutics and Cypherpunk Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

In the previous week, Coya Therapeutics had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 5 mentions for Coya Therapeutics and 2 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.44 beat Coya Therapeutics' score of 0.57 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Coya Therapeutics	Positive
Barinthus Biotherapeutics	Positive

Coya Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 242.26%. Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 452.49%. Given Barinthus Biotherapeutics' higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Coya Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.22	-$21.23M	-$1.15	N/A
Barinthus Biotherapeutics	$14.97M	1.98	-$66.43M	-$1.29	N/A

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Coya Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

Summary

Coya Therapeutics beats Barinthus Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Barinthus Biotherapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Barinthus Biotherapeutics' return on equity of -63.83% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 452.49%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ALT5 Sigma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market.

In the previous week, ALT5 Sigma and ALT5 Sigma both had 2 articles in the media. ALT5 Sigma's average media sentiment score of 1.89 beat Barinthus Biotherapeutics' score of 1.44 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company	Overall Sentiment
ALT5 Sigma	Very Positive
Barinthus Biotherapeutics	Positive

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Barinthus Biotherapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.82	-$344.51M	N/A	N/A
Barinthus Biotherapeutics	$14.97M	1.98	-$66.43M	-$1.29	N/A

Summary

Barinthus Biotherapeutics beats ALT5 Sigma on 9 of the 13 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Pyxis Oncology?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Barinthus Biotherapeutics has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.98	-$66.43M	-$1.29	N/A
Pyxis Oncology	$13.86M	7.77	-$79.62M	-$1.31	N/A

Barinthus Biotherapeutics presently has a consensus price target of $4.00, indicating a potential upside of 452.49%. Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 301.96%. Given Barinthus Biotherapeutics' higher possible upside, equities analysts plainly believe Barinthus Biotherapeutics is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Barinthus Biotherapeutics has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat Barinthus Biotherapeutics' score of 1.44 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Positive
Pyxis Oncology	Very Positive

Barinthus Biotherapeutics' return on equity of -63.83% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Pyxis Oncology	N/A	-135.60%	-85.00%

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Barinthus Biotherapeutics beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Oncolytics Biotech?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Barinthus Biotherapeutics' return on equity of -63.83% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Barinthus Biotherapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 452.49%. Oncolytics Biotech has a consensus target price of $8.50, suggesting a potential upside of 949.38%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Oncolytics Biotech has lower revenue, but higher earnings than Barinthus Biotherapeutics. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.98	-$66.43M	-$1.29	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Barinthus Biotherapeutics has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

In the previous week, Barinthus Biotherapeutics and Barinthus Biotherapeutics both had 2 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 1.44 beat Oncolytics Biotech's score of 0.63 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Positive
Oncolytics Biotech	Positive

Summary

Barinthus Biotherapeutics and Oncolytics Biotech tied by winning 7 of the 14 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.41M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-0.56	10.40	20.93	22.06
Price / Sales	1.98	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	0.40	8.06	10.47	6.72
Net Income	-$66.43M	$23.83M	$3.56B	$337.35M
7 Day Performance	9.70%	-2.82%	-1.11%	-2.54%
1 Month Performance	8.06%	2.22%	1.28%	1.42%
1 Year Performance	-26.90%	37.70%	21.20%	24.71%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	2.2465 of 5 stars	$0.72 +0.6%	$4.00 +452.5%	-27.6%	$29.41M	$14.97M	N/A	107	Short Interest Decrease
CYPH Cypherpunk Technologies	0.6258 of 5 stars	$1.07 -7.8%	N/A	+80.2%	$113.92M	N/A	N/A	40	Positive News
COYA Coya Therapeutics	3.0747 of 5 stars	$4.77 +1.3%	$16.00 +235.4%	-22.6%	$111.90M	$7.95M	N/A	6	News Coverage
AIFC ALT5 Sigma	0.1148 of 5 stars	$0.78 -2.0%	N/A	-93.6%	$109.73M	$24.70M	N/A	170	News Coverage Positive News
PYXS Pyxis Oncology	3.7145 of 5 stars	$1.73 +6.1%	$6.83 +295.0%	+25.2%	$109.60M	$13.86M	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. CYPH, COYA, AIFC, PYXS, and ONCY

How does Barinthus Biotherapeutics compare to Cypherpunk Technologies?

Summary

How does Barinthus Biotherapeutics compare to Coya Therapeutics?

Summary

How does Barinthus Biotherapeutics compare to ALT5 Sigma?

Summary

How does Barinthus Biotherapeutics compare to Pyxis Oncology?

Summary

How does Barinthus Biotherapeutics compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. CYPH, COYA, AIFC, PYXS, and ONCY

How does Barinthus Biotherapeutics compare to Cypherpunk Technologies?

Which has more risk & volatility, BRNS or CYPH?

Which has better earnings & valuation, BRNS or CYPH?

Do insiders and institutionals hold more shares of BRNS or CYPH?

Does the media prefer BRNS or CYPH?

Is BRNS or CYPH more profitable?

Do analysts recommend BRNS or CYPH?

Summary

How does Barinthus Biotherapeutics compare to Coya Therapeutics?

Does the media favor COYA or BRNS?

Do analysts rate COYA or BRNS?

Is COYA or BRNS more profitable?

Which has stronger earnings and valuation, COYA or BRNS?

Do insiders & institutionals believe in COYA or BRNS?

Which has more risk & volatility, COYA or BRNS?

Summary

How does Barinthus Biotherapeutics compare to ALT5 Sigma?

Is AIFC or BRNS more profitable?

Do analysts prefer AIFC or BRNS?

Which has more risk and volatility, AIFC or BRNS?

Does the media favor AIFC or BRNS?

Do insiders & institutionals hold more shares of AIFC or BRNS?

Which has stronger earnings & valuation, AIFC or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Pyxis Oncology?

Which has stronger valuation & earnings, BRNS or PYXS?

Do analysts prefer BRNS or PYXS?

Which has more risk & volatility, BRNS or PYXS?

Does the media prefer BRNS or PYXS?

Is BRNS or PYXS more profitable?

Do insiders and institutionals have more ownership in BRNS or PYXS?

Summary

How does Barinthus Biotherapeutics compare to Oncolytics Biotech?

Is BRNS or ONCY more profitable?

Do analysts recommend BRNS or ONCY?

Which has better valuation and earnings, BRNS or ONCY?

Do institutionals and insiders have more ownership in BRNS or ONCY?

Which has more volatility & risk, BRNS or ONCY?

Does the media refer more to BRNS or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools